The heparin binding domain of insulin-like growth factor binding protein (IGFBP)-3 increases susceptibility of IGFBP-3 to proteolysis

Hormone and Metabolic Research

Volumn 31, Issue 2-3, 1999, Pages 216-225

  Durham, Susan K ^a   Suwanichkul, A ^a   Hayes, J D ^b   Herington, A C ^c   Powell, David R ^a,d   Campbell, P G ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^d Texas Children's Hospital   (United States)

Author keywords

IGF; Plasma; Prekallikrein; Serum; Kallikrein

Indexed keywords

AMINO ACID; BLOOD CLOTTING FACTOR 12A; ENZYME PRECURSOR; HEPARIN; PREKALLIKREIN; PROTEINASE; PYROXYLIN; SODIUM CHLORIDE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; BINDING AFFINITY; IMMUNOBLOTTING; IMMUNORADIOMETRIC ASSAY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ANIMALIA; CRICETINAE; INSECTA;

EID: 0032946967     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-978722     Document Type: Article

References (41)

1. 1. Shimasaki S, Shimonaka M, Zhang H-P, Ling N. Identification of five different insulin-like growth factor binding proteins (IGFBPs) from adult rat serum and molecular cloning of a novel IGFBP-5 in rat and human. J Biol Chem 1991; 266: 10646-53
2. 2. Shimasaki S, Gao L, Shimonaka M, Ling N. Isolation and molecular cloning of insulin-like growth factor binding protein-6. Mol Endocrinol 1991; 5: 938-48
3. 3. Rechler MM. Insulin-like growth factor binding proteins. Vitam Horm 1993; 47: 1-114
4. 4. Martin JL, Baxter RC. Insulin-like growth factor binding proteins from human plasma. J Biol Chem 1986; 261: 8754-60
5. 5. Baxter RC, Martin JL. 1986 Radioimmunoassay of growth hormone-dependent insulin-like growth factor binding protein in human plasma. J Clin Invest 1986; 78: 1504-12
6. 6. Baxter RC, Martin JL, Beniac VA. High molecular weight insulin-like growth factor binding protein complex. J Biol Chem 1989; 264: 11843-8
7. 7. Leong SR, Baxter RC, Camerato T, Dai J, Wood WI. Structure and functional expression of the acid-labile subunit of the insulin-like growth factor binding protein complex. Mol Endocrinol 1992; 6: 870-6
8. 8. Conover CA, Ronk M, Lombana F, Powell DR. Structural and biological characterization of bovine insulin-like growth factor binding protein-3. Endocrinology 1990; 127: 2795-2803
9. 9. Campbell PG, Novak JF, Yanosick TB, McMaster JH. Involvement of the plasmin system in dissociation of the insulin-like growth factor-binding protein complex. Endocrinology 1992; 130: 1401-12
10. 10. Frost VJ, Macaulay VM, Wass JAM, Holly JMP. Proteolytic modification of insulin-like growth factor-binding proteins: comparison of conditioned media from human cell lines, circulating proteases and characterized enzymes. J Endocrinol 1993; 138: 545-54
11. 11. Blat C, Villaudy J, Binoux M. In vivo proteolysis of serum insulin-like growth factor (IGF) binding protein-3 results in increased availability of IGF to target cells. J Clin Invest 1994; 93: 2286-90
12. 12. Lalou C, Silve C, Rosato R, Segovia B, Binoux M. Interactions between insulin-like growth factor-I (IGF-I) and the system of plasminogen activators and their inhibitors in the control of IGF-binding protein-3 production and proteolysis in human osteosarcoma cells. Endocrinology 1994; 135: 2318-26
13. 13. Angelloz-Nicoud P, Binoux M. Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3). Endocrinology 1995; 136: 5485-92
14. 14. Lee CY, Rechler MM. Proteolysis of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in 150-kilodalton IGFBP complexes by a cation-dependent protease activity in adult rat serum promotes the release of bound IGF-I. Endocrinology 1996; 137: 2051-8
15. 15. Durham SK, Mohan S, Liu F, Baker BK, Lee PDK, Hintz RL, Conover CA, Powell DR. Bioactivity of a 29 kD IGFBP-3 fragment present in excess in chronic renal failure serum. Ped Res 1997; 42: 335-41
16. 16. Fowlkes JL, Enghild JJ, Suzuki K, Nagase H. Matrix metalloproteases degrade insulin-like growth factor binding protein-3 in dermal fibroblast cultures. J Biol Chem 1994; 269: 25742-6
17. 17. Fielder PJ, Rosenfeld RG, Graves HCB, Grandbois K, Maack CA, Sawamura S, Ogawa Y, Sommer A, Cohen P. Biochemical analysis of prostate-specific antigen-proteolysed insulin-like growth factor binding protein. Growth Regul 1994; 1: 164-72
18. 18. Conover CA, DeLeon DD. Acid-activated insulin-like growth factor binding protein-3 proteolysis in normal and transformed cells. J Biol Chem 1994; 269: 7076-80
19. 19. Andress DL, Loop SM, Zapf J, Kiefer MC. Carboxy-truncated insulin-like growth factor binding protein-5 stimulates mitogenesis in osteoblast-like cells. Biochem Biophys Res Commun 1993; 195: 25-30
20. 20. Burch WM, Correa J, Shively JE, Powell DR. The 25 kiloDalton insulin-like growth factor (IGF) binding protein inhibits both basal and IGF-I-mediated growth of chick embryo pelvic cartilage in vitro. J Clin Endocrinol Metab 1990; 70: 173-80
21. 21. Herwald H, Renne T, Meijers JCM, Chung DW, Page JD, Colman RW, Muller Esterl W. Mapping of the discontinuous kininogen binding site of prekallikrein. J Biol Chem 1996; 271: 13061-7
22. 22. Cubbage ML, Suwanichkul A. , Powell DR. Insulin-like growth factor binding protein-3 (IGFBP-3): Organization of the human chromosomal gene and demonstration of promoter activity. J Biol Chem 1990; 265: 12642-9
23. 23. Wcod WI, Cachianes G, Henzel WJ, Winslow GA, Spencer SA, Hellmiss R, Martin JL, Baxter RC. Cloning and expression of the growth-hormone-dependent insulin-like growth factor-binding protein. Mol Endocrinol 1988; 2: 1178-85
24. 24. Suwanichkul A, Allander SV, Morris SL, Powell DR. Glucocorticoids and insulin regulate expression of the human gene for insulin-like growth factor binding protein-1 through proximal promoter elements. J Biol Chem 1994; 269: 30835-41
25. 25. Spratt SK, Tatsuno GP, Yamanaka MK, Ark BC, Detmer J, Mascarenhas D, Flynn J, Talkington-Verser C, Spencer EM. Cloning and expression of human insulin-like growth factor binding protein 3. Growth Factors 1990; 3: 63-72
26. 26. Veloso D, Colman RW. Western blot analyses of prekallikrein and its activation products in human plasma. Thromb Haem 1991; 65: 382-8
27. 27. Liu F, Hintz RL, Khare A, DiAugustine RP, Powell DR, Lee PDK. Immunoblot studies of the IGF-related acid-labile subunit. J Clin Endocrinol Metab 1994; 79: 1883-6
28. 28. Booth BA, Boes M, Andress DL, Dake BL, Kiefer MC, Maack C, Linhardt RJ, Bar K, Caldwell EEO, Weiler J, Bar RS. IGFBP-3 and IGFBP-5 association with endothelial cells: Role of C-terminal heparin binding domain. Growth Regul 1995; 5: 1-7
29. 29. Ooi GT, Aguilar M, Hearn MTW, Herington AC. Relationship of a low molecular weight (16K) IGF-inhibitor/binding protein to the native IGF-binding proteins of human serum. In: Hintz RL, Drop SLS (eds). The insulin-like growth factor binding proteins. Amsterdam, The Netherlands. Excerpta Medica 1989: 231-6
30. 30. Chung DW, Fujikawa K, McMullen BA, Davie EW. Human plasma prekallikrein, a zymogen to a serine protease that contains four tandem repeats. Biochemistry 1986; 25: 2410-7
31. 31. Meier HL, Pierce JV, Colman RW, Kaplan AP. Activation and function of human Hageman factor and the role of high molecular weight kininogen and prekallikrein. J Clin Invest 1977; 60: 18-31
32. 32. Page JD, You J-L, Harris RB, Colman RW. Localization of the binding site on plasma kallikrein for high-molecular-weight kininogen to both Apple 1 and Apple 4 domains of the heavy chain. Arch Biochem Biophys 1994; 314: 159-64
33. 33. Herwald H. Jahnen-Dechen W, Alla SA, Hock J, Bouma BN, Muller-Esterl W. Mapping of the high molecular weight kininogen binding site of prekallikrein. J Biol Chem 1993; 268: 14527-35
34. 34. Mandle RJ, Colman RW, Kaplan AP. Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma. Proc Natl Acad Sci USA 1976; 73: 4179-83
35. 35. Baxter RC. Circulating levels and molecular distribution of the acid-labile (α) subunit of the high molecular weight insulin-like growth factor binding protein complex. J Clin Endocrinol Metab 1990; 70: 1347-53
36. 36. Heding A, Gill R, Ogawa Y, DeMeyts P, Shymko RM. Biosensor measurement of the binding of insulin-like growth factors 1 and 2 and their analogues to the insulin-like growth factor binding protein-3. J Biol Chem 1996; 271: 13948-52
37. 37. Lee Y-L, Hintz RL, James PM, Lee PDK, Shively JE, Powell DR. Insulin-like growth factor (IGF) binding protein cDNA from human HEP G2 hepatoma cells: Predicted protein sequence suggests an IGF binding domain different from those of the IGF-I and IGF-II receptors. Mol Endocrinol 1988; 2: 404-11
38. 38. Campbell PG, Andress DL. The heparin binding region of insulin-like growth factor binding protein-5 (IGFBP-5) regulates plasmin degradation of IGFBP-5. Amer J Physiol 1997; 273: E996-E1004
39. 39. Baxter RC, Firth SM. Modulation of human IGF binding protein-3 activity by structural modification. Prog Growth Factor Res 1995; 6: 215-22
40. 40. Kaplan AP, Silverberg M. The coagulation-kinin pathway of human plasma. Blood 1987; 70: 1-15
41. 41. Lalou C, Lassarre C, Binoux M. A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin. Endocrinology 1996; 137: 3206-12